ADAMANT
ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING
| Coordinatore | ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Organization address
address: Via Giuseppe La Masa 19 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Sito del progetto | http://www.adamant-fp7.eu |
| Totale costo | 3˙918˙400 € |
| EC contributo | 3˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-04-01 - 2011-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Organization address
address: Via Giuseppe La Masa 19 contact info |
IT (MILANO) | coordinator | 0.00 |
| 2 |
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH
Organization address
address: Raemistrasse 101 contact info |
CH (ZUERICH) | participant | 0.00 |
| 3 |
FONDAZIONE SENDO
Organization address
address: Corso Venezia 18 contact info |
IT (MILANO) | participant | 0.00 |
| 4 |
FRIEDRICH-SCHILLER-UNIVERSITAT JENA
Organization address
address: FURSTENGRABEN 1 contact info |
DE (JENA) | participant | 0.00 |
| 5 |
KEMOTECH SRL
Organization address
address: Via Roma contact info |
IT (CAGLIARI) | participant | 0.00 |
| 6 |
PHILOCHEM AG
Organization address
address: WOLFGANG PAULI STRASSE 10 contact info |
CH (ZURICH) | participant | 0.00 |
| 7 |
UNIVERSITE DE LIEGE
Organization address
city: LIEGE contact info |
BE (LIEGE) | participant | 0.00 |
| 8 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
| 9 |
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Organization address
address: De Boelelaan 1105 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can display a preferential accumulation in primary and metastatic tumor lesions already few hours after intravenous administration. Certain monoclonal antibody derivatives can remain on the neoplastic mass for several days, thus enabling the slow release of potent cytotoxics or the continuous action of bioactive agents such as cytokines or therapeutic radionuclides. The ADAMANT Project aims at the generation of anticancer agents of superior quality, which rely on the antibody-based delivery of cytotoxics, radionuclides or immunostimulatory cytokines to either vascular tumor antigens or to tumor cell membranes. While clinically-validated antibodies will allow the rapid development of therapeutic strategies based on novel antibody derivatives, innovative perfusion-based chemical proteomic technologies will facilitate the discovery of accessible and abundant tumor-associated antigens, ideally suited for the targeted delivery of bioactive agents to cancer sites. Imaging methodologies will guide us in the selection of antigens, antibodies and therapeutic agents with optimal pharmacokinetis and pharmacodynamics. Finally, therapy studies in tumor-bearing mice, featuring the use of antibody-derivatives in combination with other anti-cancer drugs (cytotoxic, biological, vascular disrupting agents) will provide insights about how to best translate the results of the ADAMANT Project to clinical development. The Project will be truly successful if at least one antibody-based tumor targeting agent enters full-blown industrial development programs by the end of the ADAMANT Project.'
Introduzione (Teaser)
European researchers used the selective binding ability of antibody molecules and cancer-specific antigens to deliver drugs directly to tumour sites. This approach boasts low toxicity and high specificity, raising anti-cancer immune responses through the targeted delivery of cytokines.